Home LiteratureArticle Details

PMID: 1677827 Published · ppublish English Clinical Trial Journal Article Research Support, U.S. Gov't, P.H.S.

Phase II trial of taxol in patients with metastatic renal cell carcinoma.

Cancer investigation ·Vol. 9 ·No. 2 ·1991-00-00 ·Pages 133-6

Einzig AI, Gorowski E, Sasloff J, Wiernik PH

Abstract

Based on results of previous Phase I studies, 18 patients with documented metastatic renal cell carcinoma received Taxol 250 mg/m2 as a 24-h infusion, repeated every 21 days in this Phase II study. All patients received premedication with dexamethasone, diphenhydramine, and cimetidine. There were no responses in the 18 patients treated.

MeSH Terms

Adult Aged Alkaloids/therapeutic use Antineoplastic Agents, Phytogenic/therapeutic use Carcinoma, Renal Cell/drug therapy Drug Evaluation Female Humans Kidney Neoplasms/drug therapy Male Middle Aged Neoplasm Metastasis Paclitaxel

Chemicals

Alkaloids Antineoplastic Agents, Phytogenic Paclitaxel

Authors & Affiliations

4 authors, click to expand affiliations / ORCID

Einzig A I

Albert Einstein Cancer Center, Montefiore Medical Center, Bronx, New York.

Gorowski E

Sasloff J

Wiernik P H

Article Info

Journal

Cancer investigation

Abbr.

Cancer Invest

ISSN

0735-7907

DOI

10.3109/07357909109044223

Published

1991-00-00

Pages

133-6

Language

English

Region

England

NLM ID

8307154

Subset

Grants

NCI NIH HHS · 2P30CA1330-15 · United States

External Links

PubMed source DOI: 10.3109/07357909109044223 View journal details

Analysis Services

Phase II trial of taxol in patients with metastatic renal cell carcinoma.

Contact

WeChat Official Account